Shares of Large-cap health care company AbbVie moved -0.4 this evening, and are now trading at $138.06 per share. On the other hand, the average analyst target price for the stock is $169.72.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
AbbVie Investors Should Consider This:
-
AbbVie has moved -9.0% over the last year.
-
The company has a price to earnings growth (PEG) ratio of -2.93. A number between 0 and 1 could mean that the market is undervaluing AbbVie's estimated growth potential
-
Its Price to Book (P/B) ratio is 20.15
-
AbbVie currently returns an annual dividend yield of 4.3%.
Understanding AbbVie's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 56,023,000 | 38,637,000 | 31 | 0.0 |
| 2022 | 58,054,000 | 39,937,000 | 31 | -3.12 |
| 2021 | 56,197,000 | 38,273,000 | 32 | 28.0 |
| 2020 | 45,804,000 | 34,441,000 | 25 | -35.9 |
| 2019 | 33,266,000 | 20,283,000 | 39 | 105.26 |
| 2018 | 32,753,000 | 26,370,000 | 19 |
Over the last 6 years, AbbVie's operating margins have averaged 29.5%, which is better than the 12.02% Pharmaceutical industry average. We also note that the company's operating margins have a high coefficient of variability at 180.9%. In addition, the firm's margins benefit from a 8.5% yearly growth rate.
